Literature DB >> 36248756

Salvage Mastectomy Is not the Treatment of Choice for Aggressive Subtypes of Ipsilateral Breast Cancer Recurrence: A Single-Institution Retrospective Study.

Damiano Gentile1, Andrea Sagona1, Ruggero Spoto2, Davide Franceschini2, Stefano Vaccari3, Valeriano Vinci4, Ersilia Biondi5, Lorenzo Scardina5, Corrado Tinterri1,4.   

Abstract

Objective: Patients with triple-negative (TN) or human epidermal growth factor 2 (HER2)-enriched ipsilateral breast cancer recurrence (IBCR) seem to be excluded from a second breast-conserving surgery (BCS) under the assumption that salvage mastectomy would provide better oncological outcomes. The objective of this study was to describe the clinical features of these patients, to compare the two surgical alternatives (salvage mastectomy versus second BCS) in terms of oncological results, and to identify independent factors influencing prognosis and surgical treatment. Materials and
Methods: We retrospectively reviewed all the consecutive patients with histologically confirmed TN or HER2-enriched IBCR. Disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), and breast cancer-specific survival (BCSS) were analyzed and compared between the two groups.
Results: Eighty-five patients were affected by TN or HER2-enriched IBCR. The majority of patients (72.9%) were treated with salvage mastectomy. There was no significant difference in terms of DFS between patients receiving a second BCS or mastectomy (p = 0.596). However, patients undergoing a second BCS had significantly better DDFS, OS and BCSS compared to mastectomy (p = 0.009; p = 0.002; p = 0.001, respectively). Tumor dimension <16 mm was found to significantly increase the probability of receiving a second BCS and positively affects recurrence and survival outcomes. Salvage mastectomy represents an independent poor prognostic factor for OS and BCSS.
Conclusion: Salvage mastectomy is not always necessary and it does not seem to increase survival compared to a second BCS. In patients with small aggressive subtypes of IBCR, a second conservative approach can still be evaluated and offered, presenting acceptable loco-regional control and survival. ©Copyright 2022 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.

Entities:  

Keywords:  Breast cancer; HER2; breast-conserving surgery; recurrence; triple-negative breast cancer

Year:  2022        PMID: 36248756      PMCID: PMC9521294          DOI: 10.4274/ejbh.galenos.2022.2022-5-3

Source DB:  PubMed          Journal:  Eur J Breast Health


  30 in total

1.  Prosthetic breast reconstruction in previously irradiated breasts: A meta-analysis.

Authors:  Kyeong-Tae Lee; Goo-Hyun Mun
Journal:  J Surg Oncol       Date:  2015-09-16       Impact factor: 3.454

2.  Ipsilateral Breast Tumor Reappearance and Contralateral Breast Cancer after Primary Breast Cancer Treatment: A Comprehensive Retrospective Study of 15,168 Patients.

Authors:  Giovanni Corso; Patrick Maisonneuve; Giorgia Irene Santomauro; Alessandra Margherita De Scalzi; Antonio Toesca; Fabio Domenico Bassi; Gabriel Farante; Pietro Caldarella; Mattia Intra; Viviana Galimberti; Paolo Veronesi
Journal:  Oncology       Date:  2018-05-30       Impact factor: 2.935

3.  Breast reconstruction outcomes after nipple-sparing mastectomy and radiation therapy.

Authors:  Richard G Reish; Alex Lin; Nicole A Phillips; Jonathan Winograd; Eric C Liao; Curtis L Cetrulo; Barbara L Smith; William G Austen; Amy S Colwell
Journal:  Plast Reconstr Surg       Date:  2015-04       Impact factor: 4.730

4.  Safety for Repeat Lumpectomy Without Radiotherapy for Ipsilateral Breast Tumor Recurrence.

Authors:  Makoto Ishitobi; Reiko Fukui; Yoko Hashimoto; Nobuyoshi Kittaka; Takahiro Nakayama; Yasuhiro Tamaki
Journal:  Anticancer Res       Date:  2017-09       Impact factor: 2.480

5.  Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.

Authors:  Hee Jeong Kim; Wonshik Han; On Vox Yi; Hee Chul Shin; Soo-Kyung Ahn; Beom Seok Koh; Hyeong-Gon Moon; Jong Han You; Byung Ho Son; Sei Hyun Ahn; Dong-Young Noh
Journal:  Breast Cancer Res Treat       Date:  2011-08-19       Impact factor: 4.872

6.  Repeat breast-conserving therapy for ipsilateral breast cancer recurrence: A systematic review.

Authors:  Coco J E F Walstra; Robert-Jan Schipper; Ingrid G M Poodt; Yvonne E van Riet; Adri C Voogd; Maurice J C van der Sangen; Grard A P Nieuwenhuijzen
Journal:  Eur J Surg Oncol       Date:  2019-02-10       Impact factor: 4.424

7.  Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events.

Authors:  U Veronesi; E Marubini; M Del Vecchio; A Manzari; S Andreola; M Greco; A Luini; M Merson; R Saccozzi; F Rilke
Journal:  J Natl Cancer Inst       Date:  1995-01-04       Impact factor: 13.506

8.  Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.

Authors:  Umberto Veronesi; Natale Cascinelli; Luigi Mariani; Marco Greco; Roberto Saccozzi; Alberto Luini; Marisel Aguilar; Ettore Marubini
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

9.  Repeat Breast-Conserving Surgery Versus Salvage Mastectomy for Ipsilateral Breast Tumour Recurrence After Breast-Conserving Surgery in Breast Cancer Patients: A Meta-Analysis.

Authors:  Caiqin Mo; Weihong Ruan; Junyu Lin; Huaying Chen; Xiangjin Chen
Journal:  Front Oncol       Date:  2021-11-23       Impact factor: 6.244

10.  Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial.

Authors:  Douglas W Arthur; Kathryn A Winter; Henry M Kuerer; Bruce Haffty; Laurie Cuttino; Dorin A Todor; Pramila Rani Anne; Penny Anderson; Wendy A Woodward; Beryl McCormick; Sally Cheston; Walter M Sahijdak; Daniel Canaday; Doris R Brown; Adam Currey; Christine M Fisher; Reshma Jagsi; Jennifer Moughan; Julia R White
Journal:  JAMA Oncol       Date:  2020-01-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.